Skip to main content

Wound

0
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

MolecuLight
MolecuLightON - Toronto
3 programs
MolecuLight PIDN/A1 trial
Point-spectroscopy TrialN/A1 trial
Positive Predictive Value (PPV) of Pseudomonas AeruginosaN/A1 trial
Active Trials
NCT03967405Unknown50Est. Mar 2021
NCT05183698Unknown50Est. Dec 2022
NCT03290690Unknown65Est. Jul 2020
Solventum
SolventumMN - St. Paul
1 program
3M™ V.A.C.® Peel and Place DressingN/A1 trial
Active Trials
NCT06625385Recruiting90Est. May 2027
Vomaris Innovations
1 program
ProcelleraN/A1 trial
Active Trials
NCT01938066Completed30Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Solventum3M™ V.A.C.® Peel and Place Dressing
MolecuLightPoint-spectroscopy Trial
MolecuLightMolecuLight PID
MolecuLightPositive Predictive Value (PPV) of Pseudomonas Aeruginosa
Vomaris InnovationsProcellera

Clinical Trials (5)

Total enrollment: 285 patients across 5 trials

NCT06625385Solventum3M™ V.A.C.® Peel and Place Dressing

A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing

Start: Jan 2025Est. completion: May 202790 patients
N/ARecruiting
NCT05183698MolecuLightPoint-spectroscopy Trial

Point-spectroscopy Trial

Start: Jan 2022Est. completion: Dec 202250 patients
N/AUnknown
NCT03967405MolecuLightMolecuLight PID

A Prospective Evaluation of Clinical Equivalence Between iX and PID

Start: Aug 2019Est. completion: Mar 202150 patients
N/AUnknown
NCT03290690MolecuLightPositive Predictive Value (PPV) of Pseudomonas Aeruginosa

Positive Predictive Value (PPV) of Pseudomonas Aeruginosa

Start: Aug 2017Est. completion: Jul 202065 patients
N/AUnknown
NCT01938066Vomaris InnovationsProcellera

Procellera and Negative Pressure Therapy for Acute Wounds

Start: Jul 2013Est. completion: Dec 201430 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 285 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.